Compare ASTI & RNAZ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ASTI | RNAZ |
|---|---|---|
| Founded | 2005 | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Semiconductors | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 30.0M | 27.9M |
| IPO Year | 2014 | 2021 |
| Metric | ASTI | RNAZ |
|---|---|---|
| Price | $2.14 | $1.63 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 254.9K | 48.0K |
| Earning Date | 11-09-2026 | 08-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 70.23 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $10,398,149.00 | N/A |
| Revenue This Year | $987.62 | N/A |
| Revenue Next Year | $2,579.52 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 163.25 | N/A |
| 52 Week Low | $1.40 | $1.52 |
| 52 Week High | $9.87 | $15.90 |
| Indicator | ASTI | RNAZ |
|---|---|---|
| Relative Strength Index (RSI) | 30.14 | 41.61 |
| Support Level | N/A | $1.55 |
| Resistance Level | $3.22 | $2.39 |
| Average True Range (ATR) | 0.19 | 0.21 |
| MACD | -0.03 | 0.10 |
| Stochastic Oscillator | 5.86 | 24.14 |
Ascent Solar Technologies Inc is a solar technology company that manufactures and sells photovoltaic (PV) solar modules that are flexible, durable, and possess attractive power to weight and power to area performance. Its technology provides renewable power solutions to high-value production and specialty solar markets where traditional rigid solar panels are not suitable, including space power beaming, aerospace, satellites, near earth orbiting vehicles, fixed wing unmanned aerial vehicles (UAV), aquatic, terrestrial, and other weight-sensitive markets with transformational high quality, value added product applications. It operates in single PV segment that sells PV products and engineering services and currently, is selling it in North America.
TransCode Therapeutics Inc is a clinical-stage biotechnology company engaged in the development of RNA-based therapeutics and immuno-oncology treatments for cancer. The company's lead candidate, TTX-MC138, targets microRNA-10b and has completed a Phase 1a clinical trial, while it is also advancing additional product candidates, including a cancer vaccine and an oncolytic immunotherapy platform.